• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Emerging Biopharma

money financing funds
Biotech

Fierce Biotech Fundraising Tracker: Aro, Vivodyne & more

Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker.
Gabrielle Masson , Max Bayer , Annalee Armstrong Nov 28, 2023 1:08pm
Biotech MA Tracker

Fierce Biotech M&A Tracker 2023: T3, Freeline & more

Nov 22, 2023 10:45am
Jefferies

Optimism at Jefferies, but don't expect IPO boost soon—Sofinnova

Nov 16, 2023 3:00am
IPO initial public offering Wall Street

Lexeo drops share price at last minute to raise $100M IPO

Nov 3, 2023 8:19am
Eli Lilly ESMO pipeline 2023

The ESMO ADC Files: Lilly tries to avoid 'shiny new objects'

Oct 24, 2023 5:45am
gamble bet slots Vegas dice cards poker

Biopharma won’t stop betting big on M&A earnouts as payouts slow

Oct 17, 2023 6:00am
More News

Orphan cell, gene therapies more likely to reach approval: study

Oct 11, 2023 12:00pm

Agomab uses $100M series C to push Crohn's drug through phase 2

Oct 11, 2023 8:50am

After pandemic sugar rush, biotechs eye stigmatized fundraisings

Oct 9, 2023 7:00am

Novo Nordisk's owner widens investment strategy beyond biotech

Oct 6, 2023 9:55am
See more stories

Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy